

epitomee

shaping your health

Ingestible therapeutic platform

Investor Presentation

Tel-Aviv | November 2021





This presentation (the “**Presentation**”) is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the “**Company**”) and should not be regarded as a recommendation or an opinion on such matters. The information included in this Presentation is not comprehensive and does not include all the information with respect to the Company and its business required for any decision concerning an investment in the Company’s securities. This Presentation includes forecasts, estimates, assessments, expectations and other information, intent or belief pertaining to future events and/or matters, which constitute “forward-looking statements” as defined in the Securities Law 5728-1968, which is based on current expectations, projections and assumptions about future events. Actual results may differ materially due to variety of factors, some of which the Company has no control over and cannot be reasonably foreseen at this date, including, but not limited to: dependency on third parties engaged by or who contracts the Company and its services, change in the overall economy; the duration and severity of the COVID-19 (coronavirus) pandemic and its impact on the Company and on local and global economy and the Company’s ability to manage and develop its business. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this Presentation. Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources the accuracy of such information and the assumptions on which such information is based have not been independently verified. The past performance information contained herein is not indicative of future results and there can be no assurance that the Company will achieve comparable results or that the Company will be able to implement its investment strategy or achieve any investment objective.

Management Team



Shimon Eckhouse, PhD
Co-founder and Chairman

Founder of Syneron Nasdaq: ELOS & Lumenis
Nasdaq: LMNS, Sofwave medical TLV: SOFW and many others



Dan Hashimshony, PhD
Chief Executive Officer

Founder & CEO-Dune Medical Devices
Chief Scientist X-technologies, and others



Gal Aharonowitz

COO
SHL, VP R&D Lumenis,
GM Israel
Dune medical



Yael Kenen, PhD

VP Clinical Affairs
TEVA, Global Clinical drug
development director



Gil Cohen, PhD

VP R&D
SCO Dune Medical Devices,
Hebrew University of Jerusalem



Dr. Ruthie Amir, MD.

Chief Medical &
Regulatory Officer
Global VP Regulatory
Syneron, Sofwave medical.



Maya Gabrieli, CPA

Financial controller
Plastopil Hazorea LTD, KPMG

Mission Statement

Epitomee Medical has developed ingestible technology platform that enables the creation of swallowable medical devices aimed to act along the GI tract to achieve therapeutic outcomes in highly prevalent diseases



Epitomee in a nutshell

Our Technology Platform

- ▶ Self ingested device platform for targeted deployment and delivery of therapies along the GI tract

Disruptive technology addressing 2 Huge Markets

- ▶ Weight management market opportunity > \$200 b
- ▶ Biologics market opportunity > \$300 b

Strategic Partnership with Nestle



- ▶ Global commercialization and marketing by Nestle
- ▶ Deal provides immediate and mid term cash to complete the entire US Clin/Regulatory

Market Launch By Nestle H2/23

- ▶ Cleared in Europe, Cleared in Israel, 510(k) FDA trial is ongoing in the US
- ▶ Scaling up manufacturing process development toward market launch

Portfolio Of 42* Patents

- ▶ 30 Granted patents, 12 Pending patents

Strong Shareholders

- ▶ Shimon Eckhouse & XT Holdings

* Updated 18.11.21

The Epitomee platform

Device-based solutions acting along the GI tract, utilizing self-ingested, transient, shapeshifting platforms



ORAL ADMINISTRATION

Packed in a swallowable standard size capsule for easy daily use



TARGETED DEPLOYMENT

Controlled activation along the stomach, duodenum and Small intestine through pH sensitive trigger mechanism




TRANSIENT OPERATION

Set duration of interaction, followed by dissolvment and eviction through natural bowel movements



SAFE FUNCTION

Produced from approved Excipients, food additives and food contact materials



Epitomee weight management capsule

Its impact is transitory as It dissolves completely and leaves the body naturally within several hours

-  x2 Taken twice a day, before meals
-  Early sensation of fullness
-  Resulting in a lower daily caloric intake
-  Subsequent weight loss

The Capsule **expands** in the stomach into a semi rigid scaffold creating **a natural sense of fullness**




How Epitomee Works

01

INGESTING


Swallowable capsule reaches the stomach



02

SHAPESHIFTING


Expanding into a semi rigid triangular shape as a reaction to stomach's pH levels



03

RESISTING

Interacting with stomach's mechanical sensors, inducing early satiety and modified gastric emptying



04


CLEARING OUT

After several hours in the stomach, the device disintegrates in the intestine within minutes





Mechanosensory stimulation

The applied local pressure activates key pathways involved in the regulation of food intake both in the brain and the stomach



The Whole World Is Getting Fatter

Globally: 1.9 B people are overweight




Post product launch:
Immediate addressable market in USA and EU5 (BMI 27-40) 190 M people.
Potential future market - China

The stunning rise of overweight & Obesity in the US

73%
of all US adults are
overweight

1 out of
3 kids



Sources: see list on page 33

Overweight = body mass index (BMI) of 25.0–29.9 kg/m² **Obesity** = BMI at or above 30.0 kg/m² **Severe Obesity** = BMI at or above 40.0 kg/m²

Multi billion Growing market



Global Weight Management Market



Sources: see list on page 33



Clinical trial data shows safety and efficacy





In 12 week treatment



7 out of 10
Participants
completers
lost weight

N=78
>10,000
ingested capsules



The entire cohort
Reduced ~5 cm
of their waist
circumference

Clinical trial data shows additional clinical value



In 12 week treatment

PREDIABETS



~50% of prediabetic
Patients improved
their Hba1c or Glucose
levels

CARDIOVASCULAR RISK FACTOR




diastolic BP
10mmHg

systolic BP
13mmHg

21 out of the 35 high blood pressure patient
reduced their systolic BP
by 13mmHg and diastolic BP by 10mmHg

Reasons to use the Epitomee weight management solution




Weight Management & Obesity

~5% of body weight from baseline in 12 weeks



Diabetes Prevention

Reversing prediabetic In 12 weeks



Body Shaping

~2" waist circumference reduction in 12 weeks



High Blood Pressure Reduction

Over 10 mm Hg reduction In 12 weeks



Excellent safety, Drug Free

Pure Mechanosensory
Excellent safety
No device Related Serious Adverse Events with over 10,000 capsules swallowed

The Nestle – Epitomee Strategic Deal (Closed Aug 2020)

Exclusive global license to use the Epitomee product in the weight loss market

Agreement to develop and commercialize a novel weight loss and metabolic health product

Market launch planned for H2 2023



Nestle Health Science is responsible for commercialization

Epitomee is responsible for manufacturing

Deal provides immediate and mid-term cash and long-term visibility on revenue stream

The Nestle – Epitomee Deal | High Level Payments Scheme

\$64M DEVELOPMENT
MILESTONE*

\$60M SALES
MILESTONE



Up to 10%
GROWING ROYALTIES

Cost Plus Markup
ON PRODUCT

***Up to now \$17 M of the \$64 M were paid**

Business Case Example

For demonstration only. Constitutes a “forward-looking statements” as defined in the Securities Law



End user Price
\$100/month



60 Capsules
at \$1.7 per capsule



One Capsule
\$1 Net to
distributor



 \$720 per
Patient/year



0.5% of US & EU5
market
~1M Patients



For Epitomee
~ \$162 M in Revenue
+ \$58 M in Royalties

Example of the meaning of going to the market with Nestlé

For demonstration only. Constitutes a “forward-looking statements” as defined in the Securities Law



Nestlé
Market penetration*



Nestlé
Annual revenue



epitomee
Annual revenue

1%

\$2.28 B

\$423 M

(\$126M from Royalties)

3%

\$6.84 B

\$1.28 B

(\$400M from Royalties)

The numbers above are not including

- ⊗ Revenues outside Europe and USA
- ⊗ Nestlé Development Milestones Revenues 2022-2023 (47 m\$)
- ⊗ Nestlé Sales Milestones Revenues (60 m\$)
- ⊗ Revenues from New products
- ⊗ Population growth

*US & EU5 Market

Global Regulatory

In preparation for H2 2023 market launch Nestle and Epitomee regulatory teams are working towards regulatory clearances in the following territories:

-  Approved
-  In Progress
-  Target territory for market launch



Europe – Cleared for the EU market, CE mark



Israel – Cleared by the ministry of health since October 2021



USA – FDA preparation for H1 2023



Epitomee 510(k) US study design

Nonsignificant risk study

The effect of Epitomee Capsule on Body Weight in Patients with Overweight and Obesity with/without Prediabetes



Study Design

Double-blind, Placebo Controlled, Randomized, Multicenter, Adaptive Design Study.



Sample size

N=230 to 600
Final sample size determination - Q3/22



Main patient population

1. Adults, BMI 27-40 kg/m²
2. Normoglycemic and Prediabetic subjects



Primary Efficacy Endpoints

1. Average weight loss from baseline-better than control
2. Proportion of subjects who have lost at least 5% of their baseline weight > 35%



Clinical Sites - US



US sites currently in the US trial




Sites about to join

Competitive Landscape

	epitomee	Gelesis/ Plenity (medical device)	Novonordisk Wegovy (drug)	Noom (mobile application)	Allurion Ellipse (medical device)
consumer price range (monthly)	\$80-\$120	\$100	\$1200	\$59	\$1,000-1,500
Administration	1 pill per meal	3 pills per meal	By injection	Mobile app only	Inflate at the clinic then X ray
Requires a Prescription	✓	✓	✓	✗	✓
Drug free	✓	✓	✗	✓	✓
Slow gastric emptying	✓	unknown	✓	✗	Unknown
Self administered	✓	✓	✓	✓	✗

Timeline to market





Disruption of the
Biologics Market
with a novel oral
delivery **device**

The need for New Oral Delivery of Biologics

32% of all pharmaceutical market is Biologics

Treating, metabolic disease, ageing and inflammatory disorders and cancer

Small
Molecule



Biological
Molecule




Monoclonal
Antibody



Degree of Complexity and size

Most oral solution attempts involve manipulation on the drug itself – Complicated, requires new drug regulatory pathway for every application.



Current

- ▶ Biologics delivery is typically delivered by painful and burdensome injections
- ▶ Oral administration is not possible for most biologics



Future by EPITOME


Epitomee offers a novel approach
Using an ingestible device for the delivery of
biologics

Source: see on page 33

Disruptive solution for the biologics market



Global Biologics market



Targeting: Cancer, Diabetes, Autoimmune~30% of all pharma.
Biologics are typically delivered by injections

With its new approach Epitomee could disrupt the biologics market

The platform allows:



Drug-device combination regulation




Saving painful injections for patients



Saving long and expensive development trials for the industry

Sources: see list on page 33

Potential combination with multiple blockbuster biologics




Sources: see list on page 34



Development milestones - Delivery device

Pre-clinical Development



Clinical Development



Very active M&A and investment market with significant value



Value
\$0.67b

Gelesis, valued \$0.67b, November 2021, to be listed Q4/21

Gelesis is competing with Epitee/Nestlé with a swallowable transient device for weight management.



Value
\$3.7b

Noom, raised \$540m, at a value of 3.7b, plans to go public during 2022

Noom is a mobile app offering lifestyle advice and weight loss programs.



Value
\$1.35b

Novo Nordisk Acquired Emisphere Technologies for \$1.35b, November 2020.

Emisphere is a drug delivery company with proprietary technologies that enable oral formulations of therapeutics.



Multi billions
strategics

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy Direct to consumer launch, October 2021



Multi billions
strategics

Eli Lilly compete with Novo Nordisk with a new weight loss drug named Tirzepatide, reported March 2021



Multi billions
strategics

Boehringer Ingelheim Launches Weight-Loss Trials, april 2021



Value
\$1.3b

Rani therapeutics, went public on Aug 2021, raised \$73m, now valued at ~\$1.3b, Nasdaq:

RANI Rani is competing head-to-head with Epitee in the field of devices for oral delivery of biologics, and in similar stage as Epitee.

IP



**Multiple patent families,
covering the product
and pipeline**

Updated 18.11.21

Epitomee in a nutshell

Our Technology Platform

- ▶ Self ingested device platform for targeted deployment and delivery of therapies along the GI tract

Disruptive technology addressing 2 Huge Markets

- ▶ Weight management market opportunity > \$200 b
- ▶ Biologics market opportunity > \$300 b

Strategic Partnership with Nestle



- ▶ Global commercialization and marketing by Nestle
- ▶ Deal provides immediate and mid term cash to complete the entire US Clin/Regulatory

Market Launch By Nestle H2/23

- ▶ Cleared in Europe, Cleared in Israel, 510(k) FDA trial is ongoing in the US
- ▶ Scaling up manufacturing process development toward market launch

Portfolio Of 42* Patents

- ▶ 30 Granted patents, 12 Pending patents

Strong Shareholders

- ▶ Shimon Eckhouse & XT Holdings

* Updated 18.11.21

epitomee
shaping your health

Thank you



References

Slide No. 11

- <https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm>
- <https://www.childhealthdata.org/browse/survey/results?q=8029&r=1>

Slide No. 12

- <https://www.globenewswire.com/news-release/2020/12/17/2147220/0/en/Global-Weight-Management-Industry.html>
- <https://www.alliedmarketresearch.com/weight-loss-management-diet-market>
- <https://www.marketinsightsreports.com/reports/07163079345/global-weight-loss-and-weight-management-market-size-status-and-forecast-2021-2027>
- <https://www.reportsanddata.com/report-detail/obesity-treatment-market>
- <https://www.360researchreports.com/global-obesity-treatment-market-18329373>
- <https://www.marketresearch.com/GlobalInfoResearch-v4117/Global-Obesity-Treatment-Company-Regions-14363795/>

Slide No. 25

- <https://www.statista.com/statistics/1118421/biologic-medicines-share-of-total-pharmaceutical-sales-in-oecd-countries/>

Slide No. 26

- <https://www.prnewswire.com/news-releases/global-biologics-market-opportunities-and-strategies-report-2020-covid-19-impact-and-recovery---forecast-to-2023-2025--2030-301223015.html>
- <https://www.globenewswire.com/news-release/2020/04/03/2011472/0/en/Global-Biologics-Market-to-surpass-US-456-83-8-Billion-by-2027-Says-CMI.html>
- <https://www.verifiedmarketresearch.com/product/biologics-market/>
- <https://www.coherentmarketinsights.com/market-insight/oral-biologics-market-989>
- <https://marketresearch.biz/report/oral-biologics-market/>
- <https://manometcurrent.com/exclusive-report-on-oral-biologics-market-analysis-report-2021-and-forecast-to-2029-with-different-segments-key-players/>

References

Slide No. 27

- <https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market>
- <https://www.businesswire.com/news/home/20210325005642/en/Global-TNF-Alpha-Inhibitors-Market-Report-2020-2030-COVID-19-Growth-and-Change---Market-is-Expected-to-Decline-from-40.66-Billion-in-2019-to-39.01-Billion-in-2020---ResearchAndMarkets.com>
- Basal Insulin (Long-Acting Insulin) - Market Projections to 2024 with Company Profiles & Share Analysis - ResearchAndMarkets.com | Business Wire
- Human Growth Hormone (HGH) Market | 2021 - 26 | Industry Share, Size, Growth - Mordor Intelligence
- Global Parathyroid Hormone Market Data And Industry Growth Analysis (thebusinessresearchcompany.com)
- Interferon Beta Drugs Market Size, Trends, Shares, Insights, Forecast - Coherent Market Insights